Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine/tipiracil) Published in JAMA Oncology.

Servier is willing to share data from a subgroup analysis from the global Phase III TAGS trial published in The Journal of the American Medical Association (JAMA). Results In the preplanned subgroup analysis, 221 of 507 patients with mGC or GEJ adenocarcinoma with prior gastrectomy were enrolled and randomized to receive LONSURF (n=147) or placebo (n=74) on days 1-5 and 8-12 of each 28-day treatment cycle. Results showed that treatment with LONSURF was tolerable and prolonged survival versus placebo by 6 months vs 3.4 months [95% CI, 0.57 (0.41-0.79)]. Further, the overall safety profile of...